

A compound, Transitmycin, effective against bacterial and viral pathogens

Salient features of the technology

- Transitmycin which belongs to new class of antibiotics is effective against both TB and HIV.
- The compound is effective against multiple drug resistant and extensively drug resistant strains of Mycobacterium tuberculosis as well as drug sensitive strains.
- The compound is also effective against other bacterial pathogens.
- The compound also effectively kills drug resistant, recombinant and drug sensitive strains of HIV at very low dose.
- The process of producing the compound is a simple one and does not require complex laboratory set-up which makes the compound economically viable.
- The compound is a natural product and is produced through naturally occurring microorganisms. Therefore, the compound itself or the process of producing the same are eco-friendly and does not pose any threat to environment.
- The compound shows very poor cytotoxic activity and hence can be effectively used to manufacture pharmaceutical formulations against bacterial and viral pathogens.
- It is developed by the National Institute for Research in Tuberculosis, Chennai, an institute of ICMR.
- An Indian patent application and three foreign patent applications (in USA, UK and South Africa) have been filed.




Fig. Hypothetical model of the compound, Transitmycin